Chardan Capital Sticks to Their Hold Rating for Novavax (NVAX)


In a report released today, Keay Nakae from Chardan Capital reiterated a Hold rating on Novavax (NVAX), with a price target of $7. The company’s shares closed yesterday at $0.36, close to its 52-week low of $0.34.

According to TipRanks.com, Nakae has 0 stars on 0-5 star ranking scale with an average return of -14.1% and a 31.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and BioSig Technologies Inc.

Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $1.41, which is a 292.2% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Hold rating on the stock with a $0.50 price target.

See today’s analyst top recommended stocks >>

Based on Novavax’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $43.22 million. In comparison, last year the company had a GAAP net loss of $46.35 million.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVAX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts